Science Stories
featured story
Extensive-stage small cell lung cancer remains one of the most aggressive and difficult-to-treat cancers, with most patients relapsing within months of initial therapy. Maintenance therapy may turn the period of stability after their first treatment into an opportunity to extend response and delay relapse.
In the treatment of cancer, one size does not fit all. At Jazz, our researchers are committed to discovering new possibilities for delivering innovative treatments as effectively and safely as possible.
We’re committed to developing life-changing medicines that can redefine the possibilities for life after a cancer diagnosis — in particular for patients with certain types of secondary acute myeloid leukemia (AML).